Zydus Cadila gets USFDA’s tentative nod for Carbidopa, Levodopa extended-release capsules

03 Aug 2020 Evaluate

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Carbidopa and Levodopa Extended-Release Capsules (US RLD - Rytary) in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This medication is used to treat the symptoms of Parkinson’s disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 295 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

958.90 -0.55 (-0.06%)
23-Apr-2024 15:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1483.75
Dr. Reddys Lab 5947.30
Cipla 1347.70
Zydus Lifesciences 958.90
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.